

# Metabolism of lipids IX: *Plasma lipoproteins*

Prof. Mamoun Ahram

### Resources




- This lecture
- Lippincott's Biochemistry, Ch. 18

# **Characteristics of lipoproteins**


- Lipoproteins function to
  - Solubilize and carry plasma lipids
  - Transport lipids to (and from) the tissues
- They range in size and density and have variable purposes and lipid and protein composition.

The higher the protein:lipid ratio, the higher the density



# Lipid composition of lipoproteins

- A neutral lipid core (containing TAG and cholesteryl esters) surrounded by a shell of amphipathic apolipoproteins, phospholipid, and non-esterified (free) cholesterol.
  - These amphipathic compounds are oriented such that their polar portions are exposed on the surface of the lipoprotein.
- Sources of the lipid cargo: diet (exogenous source) or de novo synthesis (endogenous source).
- Total cholesterol=LDL-C + HDL-C + VLDL-C
  - VLDL-C is calculated by dividing TAG by 5 because the TAG/cholesterol ratio is 5/1 in VLDL.
    - The goal value for total cholesterol is <200 mg/dl.




# Protein composition of lipoproteins (Apolipoproteins)




### • Functions:


- Structural (cannot be removed).
- Recognition sites for cell-surface receptors
- Activators or coenzymes for enzymes involved in lipoprotein metabolism.
- some are exchanged freely among lipoproteins.
- Classes of apolipoproteins are denoted by letters, and subclasses are designated by Roman numbers.
  - Example: apoC-I, apoC-II, and apoC-III.



# Chylomicrons

Microsomal triglyceride transfer protein (MTP) assembles the apoB protein with the lipids in the ER before transition to the Golgi, where the particles are packaged in secretory vesicles.






## Apolipoproteins



	Apolipo- protein	Molecular Weight	Chylomicron (CM)	VLDL	IDL/CM remnants	LDL	HDL
	Al	28,016	Ex	Ex			St
	All	17,414	Ex	Ex			Ex
	B100	515,000		St	St	St	
	B48	241,000	St*		St*		
	CI	6600	Ex	Ex			Ex
1	CII	8800	Ex	Ex			
	CIII	8750	Ex	Ex	Ex		Ex
	E	34,100	Ex	Ex	Ex		Ex


\*B48 is exclusive to chylomicrons and chylomicrons remnants. St, structural apolipoprotein; Ex, exchangeable apolipoprotein. Other apolipoproteins (AIV, AV, D, F, G, H, J, (a)) are beyond the scope of this review.

# Structure of chylomicrons



## **Function of apo CII**

- ApoCII interacts with the lipoprotein lipase, which exists on the cell surface of endothelial cells, activating it.
- Lipoprotein lipase degrades TAG releasing fatty acids and glycerol, which enter the tissues.
- When TAGs are removed, chylomicron remnants are formed, which contain cholesteryl esters, phospholipids, apolipoproteins, fat-soluble vitamins, and a small amount of TAGs.





 Type I hyperlipoproteinemia, familial chylomicronemia, hypertriacylglycerolemia: Deficiency of LPL or apo C-II leading to the accumulation of chylomicron-TAG in the Plasma.

## Fate of chylomicron remnant



- Chylomicron remnants bind to apoE receptors on the cell surface of hepatocytes and are taken into the by receptor-mediated endocytosis.
- The intracellular remnants are hydrolyzed to their component parts.






Type III hyperlipoproteinemia: mutations in apoE gene leading to decreased clearance of chylomicron remnants.

# Very-low-density lipoprotein






## A note about apoE



- ApoE is present in three isoforms, E-2 (the least common), E-3 (the most common), and E-4.
  - ApoE-2 binds poorly to receptors.
    - patients who are homozygotic for apoE-2 are deficient in the clearance of IDL and chylomicron remnants.
    - These individuals have familial type III hyperlipoproteinemia (familial dysbetalipoproteinemia or broad beta disease), with hypercholesterolemia and premature atherosclerosis.
  - The apoE-4 isoform confers increased susceptibility to an earlier age of onset of the late-0 onset form of Alzheimer's disease.
- APOE2: APOE3: APOE4: lipid lipid receptor receptor receptor binding binding binding C158 binding binding + binding (HDL) (HDL) C255 C255 C255 (VLDL) R112 C112 C112 N-ten C-term C-term N-term C-term



Homozygotes are at the greatest risk.



Homeostatic transcriptomic phenotype Normal cytokine production Normal phagocytosis Normal debris clearance Normal migration

Reduced/normal risk of AD

microg




DAM transcriptomic phenotype ↑ pro-inflammatory cytokine production Impaired phagocytosis Deficient debris clearance Impaired migration

Increased risk of AD

### Relation of VLDL to HDL, IDL, and LDL






# **Regulation of lipoprotein lipase**

- LPL is synthesized by adipose tissue and by cardiac and skeletal muscle.
  - The highest concentration of LPL is in the cardiac muscle.
- Expression of the tissue-specific isozymes is regulated by nutritional state and hormonal level.
  - In the fed state (elevated insulin levels), LPL synthesis is increased in adipose tissue but decreased in muscle tissue.
  - Fasting (decreased insulin) favors LPL synthesis in muscle.

### Low density lipoprotein




- Primary lipoprotein is B-100.
- Plasma cholesterol, ~70% of LDL content, is taken to peripheral tissues.
- Receptor-mediated endocytosis
- Type IIa hyperlipidemia (familial hypercholesterolemia [FH]): reduced synthesis of functional LDL receptor leading to premature atherosclerosis.
- Defective apo B-100: autosomal dominant hypercholesterolemia with reduced binding to LDL receptor.




- Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes internalization and lysosomal degradation of the receptor.
  - PCSK9 inhibitors are now available for the treatment of hypercholesterolemia.

### Lysosomal storage diseases

- Lysosomal acid lipase hydrolyzes cholesterol esters and TAG, which are then transported out.
- Wolman disease: a severe, autosomal-recessive deficiency of lysosomal acid lipase leading to massive intracellular accumulation of cholesteryl esters and triglycerides.






 Niemann-Pick disease, type C: autosomal-recessive deficiency in the transport of free cholesterol out of the lysosome.

# Fate and effects of cholesterol


6


- High intracellular cholesterol levels
  - inhibit de novo cholesterol synthesis
  - induce the degradation of HMG CoA reductase.
  - decrease the synthesis of LDL receptor through the negative regulation of SREBP-2.
- Excess cholesterol is esterified by acyl CoA:cholesterol acyltransferase (ACAT) and stored in the cells.
  - The activity of ACAT is enhanced by the increased intracellular cholesterol.



### Foam cells


- Macrophages possess high levels of unregulated scavenger receptor class A (SR-A) that can bind and endocytose LDL particles carrying oxidized lipids.
- Cholesteryl esters accumulate in macrophages, which transform into "foam" cells that form atherosclerotic plaque.
- LDL-Cholesterol is the primary cause of





# **High-density lipoprotein**

- HDL particles are formed by the addition of lipid to apo A-1 (~70% of lipoproteins in HDL), which is synthesized by the liver and intestine.
- Functions:
  - HDL provides apo CII and E to VLDL and chylomicron remnants.
  - They take up non-esterified cholesterol from peripheral tissues and return it to the liver as cholesteryl esters.




# Transport of cholesterol by HDL

6


- The liver-synthesized, nascent, HDL-bound plasma enzyme lecithin:cholesterol acyltransferase (LCAT or PCAT) esterifies the HDL-carried cholesterol by transferring the FA of carbon 2 of PC and the CE is sequestered in the HDL core.
- Lysophosphatidylcholine is carried by albumin.
- LCAT is activated by apo A-I and inhibited by cholesterol ester.
- Hepatic lipase, which degrades TAG and phospholipids, participates in the conversion of HDL2 to HDL3.

Note: Lecithin = phosphatidylcholine




# $VLDL \leftrightarrow HDL through CETP$

- Some TAGs are transferred from VLDL to HDL in an exchange reaction that concomitantly transfers cholesteryl esters from HDL to VLDL.
- This exchange is accomplished by cholesteryl ester transfer protein (CETP).
- End-result is relieving product inhibition of LCAT.
- VLDL can then be converted to IDL and LDL.



### **Reverse cholesterol transport**

- The efflux of cholesterol from peripheral cells is mediated primarily by the transport protein ABCA1.
  - Tangier disease: no ABCA1, no HDL particles, degradation of apo A-1.
- Cholesteryl ester uptake by the liver is mediated by scavenger receptor class B type 1 (SR-B1).



Defective ABCA1 causes sitosterolemia, cystic fibrosis, Xlinked adrenoleukodystrophy, respiratory distress syndrome, and liver disease.